Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies.

International Journal of Molecular Sciences
Wen-Ying LinYi-Yen Lee

Abstract

With advances in the understanding of characteristics of molecules, specific antigens on the surface of hematological malignant cells were identified and multiple therapies targeting these antigens as neoplasm treatments were developed. Among them, chimeric antigen receptor (CAR) T-cell therapy, which got United States Food and Drug Administration (FDA) approval for relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) as well as for recurrent acute lymphoblastic leukemia (ALL) within the past five years, and for r/r mantle cell lymphoma (MCL) this year, represents one of the most rapidly evolving immunotherapies. Nevertheless, its applicability to other hematological malignancies, as well as its efficacy and persistence are fraught with clinical challenges. Currently, more than one thousand clinical trials in CAR T-cell therapy are ongoing and its development is changing rapidly. This review introduces the current status of CAR T-cell therapy in terms of the basic molecular aspects of CAR T-cell therapy, its application in hematological malignancies, adverse reactions during clinical use, remaining challenges, and future utilization.

References

Feb 1, 1975·The Australian Journal of Experimental Biology and Medical Science·K J Lafferty, A J Cunningham
Nov 13, 2002·Annual Review of Immunology·Fabienne MackayJeffrey Browning
Sep 15, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Renier J BrentjensMichel Sadelain
May 27, 2008·Nature Reviews. Immunology·Weiping Zou, Lieping Chen
Feb 25, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Richard A MorganSteven A Rosenberg
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Jan 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert O CarpenterJames N Kochenderfer
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
Apr 4, 2013·Cancer Discovery·Michel SadelainIsabelle Rivière
Jul 9, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·David S RitchieH Miles Prince
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Sep 2, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Quan-Shun WangWei-Dong Han
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
May 20, 2015·Expert Opinion on Biological Therapy·Markus Chmielewski, Hinrich Abken
Jun 13, 2015·Nature Communications·Sarah A LaurentEdgar Meinl
Jul 15, 2015·Trends in Immunology·Shivani Srivastava, Stanley R Riddell
Jul 29, 2015·Proceedings of the National Academy of Sciences of the United States of America·Kathrin SchumannAlexander Marson
Oct 13, 2015·Current Opinion in Hematology·Armen MardirosLihua E Budde
Mar 24, 2016·Journal of Cellular and Molecular Medicine·Annette RomanskiTorsten Tonn

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
lymphodepletion
blood draw

Clinical Trials Mentioned

NCT03391466
NCT03575351
NCT03570892
NCT03651128
NCT03758417
NCT03548207
NCT03430011
NCT03601078
NCT03331198
NCT03070327

Software Mentioned

EVOLVE
ELIANA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Pharmacology and Therapeutics
Sarah A Holstein, Matthew A Lunning
Seminars in Hematology
Andrew H MarpleNirali N Shah
Hematological Oncology
David Sermer, Renier Brentjens
© 2021 Meta ULC. All rights reserved